The stock of BriaCell Therapeutics Corp (BCTX) has gone down by -17.05% for the week, with a -24.96% drop in the past month and a -28.52% drop in the past quarter. The volatility ratio for the week is 11.03%, and the volatility levels for the past 30 days are 14.91% for BCTX. The simple moving average for the last 20 days is -37.63% for BCTX stock, with a simple moving average of -58.89% for the last 200 days.
Is It Worth Investing in BriaCell Therapeutics Corp (NASDAQ: BCTX) Right Now?
The stock has a 36-month beta value of 1.50. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCTX is 39.67M, and at present, short sellers hold a 1.83% of that float. On December 26, 2024, the average trading volume of BCTX was 2.51M shares.
BCTX) stock’s latest price update
BriaCell Therapeutics Corp (NASDAQ: BCTX) has seen a decline in its stock price by -4.82 in relation to its previous close of 0.54. However, the company has experienced a -17.05% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-17 that PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the “Meeting Materials”) for its upcoming annual general meeting (the “Meeting”) to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the suspension of mail service in Canada from the nationwide strike of the Canadian Union of Postal Workers that commenced on November 15, 2024.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy.” The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at -34.13% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.44% of loss for the given period.
Volatility was left at 14.91%, however, over the last 30 days, the volatility rate increased by 11.03%, as shares sank -32.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.81% lower at present.
During the last 5 trading sessions, BCTX fell by -17.94%, which changed the moving average for the period of 200-days by -82.98% in comparison to the 20-day moving average, which settled at $0.8190. In addition, BriaCell Therapeutics Corp saw -91.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCTX starting from Lustig Marc, who purchase 902,935 shares at the price of $2.21 back on May 14 ’24. After this action, Lustig Marc now owns 2,542,935 shares of BriaCell Therapeutics Corp, valued at $2,000,001 using the latest closing price.
Stock Fundamentals for BCTX
The total capital return value is set at -5.53. Equity return is now at value -490.69, with -114.32 for asset returns.
Currently, EBITDA for the company is -4.77 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.65.
Conclusion
To sum up, BriaCell Therapeutics Corp (BCTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
